Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 Monotherapy and Combination with Toripalimab in Advanced Solid Tumors
NCT04773951Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tifcemalimab in melanoma, renal cell carcinoma (RCC) and urothelial carcinoma (UC), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Safety and tolerability of JS004 injection alone and in combination with Toripalimab at 2 years and Maximum tolerated dose (MTD)/recommended extended dose (RDE) at 2 years. Started Apr 2021; status: completed.
02
Drugs
tifcemalimab
03
Conditions
melanomarenal cell carcinoma (RCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04773951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04773951.